Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies

Loading...
Loading...
  • Phio Pharmaceuticals Corp PHIO stock falls despite the company announcing positive new in vivo data showing that PH-762 significantly enhanced the antitumor efficacy of HER2-targeted CAR-T cells (HER2CART) in solid tumors.
  • Compared to untreated, HER2CART cells treated with PH-762 showed statistically significant and durable inhibition of tumor growth.
  • The data provided proof-of-concept for the application of PD-1 checkpoint silencing with INTASYL in CAR-T cells before adoptive cell therapy to enhance the therapeutic efficacy of CAR-T cell therapy in solid tumors.
  • "The results showed that PH-762 achieved PD-1 silencing efficiency of ~90% in nearly 100% of the HER2CART cells used in this study," stated Dr. Simon Fricker, Phio's VP of Research.
  • "In addition, these results are achieved by merely adding PH-762 to the HER2CART cell culture media, without the need for cell delivery vehicles or vectors, and without negative impact on cell growth/survival.
  • Price Action: PHIO shares are down 14.1% at $2.19 during the market trading session on the last check Tuesday.
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefscancertumors
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...